mProX™ Human MAPK14 Stable Cell Line

Product Information

Target Family

Kinases/Enzyme

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;ACHN;Caki-1

Target Classification

Kinase Cell Lines

Target Research Area

Infectious Research

Related Diseases

Chlamydia; Coffin-Lowry Syndrome

Gene ID

Human:1432

UniProt ID

Human:Q16539

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

MAPK14 (also known as p38 MAPK) is involved in various cellular processes and has applications in different disease contexts. It is implicated in bladder cancer, where it is targeted by Talaroconvolutin-A (TalaA), a compound that suppresses bladder cancer growth by blocking the cell cycle and inducing ferroptosis. MAPK14 is one of the MAPKs to which TalaA binds, inhibiting the phosphorylation of transcription regulators and contributing to the anti-tumor effects of TalaA. Additionally, MAPK14 is identified in the context of glioma, where it is targeted by Œ±-solanine, a compound with anti-tumor activity. Inflammatory diseases are another area of application for MAPK14, as shown by its involvement in the anti-inflammatory activity of fermented pineapple juice and the potential mechanisms of the anti-osteoporotic effects of the Achyranthes bidentata-Dipsacus asper herb pair. Lastly, a potent MAPK13-14 inhibitor is shown to prevent airway inflammation and mucus production, suggesting a potential therapeutic approach for respiratory diseases. Overall, MAPK14 plays a role in multiple disease processes and has implications for targeted therapies.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human MAPK14 Stable Cell Line (S01YF-1023-PY35). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Peyton Brown (Verified Customer)

Can MAPK14 be used as a biological marker in certain diseases? Aug 22 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

MAPK14 has been identified as a potential biological marker for certain conditions, such as Cushing's syndrome (CS), due to its differential expression. Aug 22 2021

chat Casey Smith (Verified Customer)

What is the prognostic significance of MAPK14 in colorectal cancer (CRC)? Jun 23 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

High expression of MAPK14 in CRC is associated with poor clinicopathological features and poor prognoses, indicating its prognostic significance in this cancer type. Jun 23 2022

Published Data

Fig.1 MAPK14 knockdown reduced the rate of cell division.

The biological function of MAPK14 in ccRCC was further investigated by conducting a cell proliferation test in MAPK14-knockdown cells. It was observed that, following transfection with MAPK14 siRNAs for 72 hours, a significant decrease in proliferation ability was noted in the cells after MAPK14 knockdown (P < .05), as indicated by the results of the EdU test.

Ref: Liu, Junlong, et al. "Knockdown of MAPK14 inhibits the proliferation and migration of clear cell renal cell carcinoma by downregulating the expression of CDC25B." Cancer Medicine 9.3 (2020): 1183-1195.

Pubmed: 31856414

DOI: 10.1002/cam4.2795

Research Highlights

Xia, Yong. et al. "Proteomics, Transcriptomics, and Phosphoproteomics Reveal the Mechanism of Talaroconvolutin-A Suppressing Bladder Cancer via Blocking Cell Cycle and Triggering Ferroptosis." Molecular & cellular proteomics : MCP, 2023.
TalaA, a compound sourced from the endophytic fungus T. convolutispora within the Chinese herbal medicine Panax notoginseng, holds promise as a potential bladder cancer treatment. Through a series of in vitro experiments, including CCK8 assays, EdU staining, crystal violet staining, flow cytometry, living/dead cell staining, and Western blotting, researchers explored its anticancer properties. Additionally, xenograft tumor implantation studies were conducted, assessing antitumor effects via H&E and immunohistochemistry staining. Proteomics, transcriptomics, and phosphoproteomics revealed TalaA's influence on cell proliferation, DNA replication, and colony formation, indicating its potential as a bladder cancer therapy targeting MAPKs, cell cycle regulation, and ferroptosis induction.
Xia, Yong. et al. "Proteomics, Transcriptomics, and Phosphoproteomics Reveal the Mechanism of Talaroconvolutin-A Suppressing Bladder Cancer via Blocking Cell Cycle and Triggering Ferroptosis." Molecular & cellular proteomics : MCP, 2023.
Pubmed: 37866481 DOI: 10.1016/j.mcpro.2023.100672

Wang, ChunPeng. et al. "Network pharmacology-based strategy to investigate the effect and mechanism of α-solanine against glioma." BMC complementary medicine and therapies, 2023.
In this study, α-solanine, a bioactive compound derived from the Chinese herb Solanum nigrum L., was examined for its potential anti-glioma properties and underlying mechanisms. Using network pharmacology, molecular docking, and molecular biology experiments, researchers predicted α-solanine's targets and identified common targets with glioma-related genes. They pinpointed 11 hub genes and explored associated signaling pathways, such as MAP kinase activity and PI3K-Akt. Furthermore, α-solanine demonstrated the ability to hinder glioma cell proliferation and migration while promoting apoptosis. The study suggested STAT1 as a potential mediator of α-solanine's impact on glioma prognosis, paving the way for novel anti-glioma treatments.
Wang, ChunPeng. et al. "Network pharmacology-based strategy to investigate the effect and mechanism of α-solanine against glioma." BMC complementary medicine and therapies, 2023.
Pubmed: 37865727 DOI: 10.1186/s12906-023-04215-1